Ignite Creation Date:
2024-05-05 @ 11:25 PM
Last Modification Date:
2024-10-26 @ 10:33 AM
Study NCT ID:
NCT01323153
Status:
COMPLETED
Last Update Posted:
2019-07-30
First Post:
2011-03-24
Brief Title:
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome Dal-ACUTE
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
A Phase III Double-blind Randomized Placebo-controlled Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids Lipoproteins Apolipoproteins and Markers of Cardiovascular CV Risk in Patients Hospitalized for an Acute Coronary Syndrome ACS When Treatment is Initiated Within 1 Week After an ACS Dal-ACUTE
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This double-blind randomized placebo-controlled multi-center study will evaluate the safety and efficacy of dalcetrapib in patients hospitalized for an acute coronary syndrome ACS Treatment will be initiated within 1 week after the ACS Patients will be randomized to receive dalcetrapib 600 mg as daily oral doses or matching placebo The anticipated time on study treatment is 20 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None